Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ghanashyam Acharya
Baylor College of Medicine, Department: Surgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
Corneal Cystinolysis, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Upon review it was determined that the investigator's SFI could directly and significantly affect the design, conduct, or reporting of the funded research, because the consulting work was performed for on Good Manufacturing Practices and processes for development of a nanowafer technology, and the research proposal also involves development of nanowafer technology (albeit for use for different disease applications), there is a potential for the SFI to be affected by the research – ie if the research showed a certain outcome, it could make the company’s nanowafer technology more valuable. In addition, the investigator’s SFI could also be affected by the results of the funded research. Therefore, the RCOIC found that an FCOI (Financial Conflict of Interest) exists for this investigator's SFI with Corneal Cystinolysis, Inc.
OCULAR DRUG DELIVERY NANOWAFER THERAPEUTIC TO TREAT CORNEAL NEOVASCULARIZATION
Project Narrative Eye injuries represents a major public health problem that can lead to impaired visual function and eventual blindness. This research endeavor focuses on the development of an ocular drug delivery nanowafer therapeutic to treat corneal neovascularization and eye injuries. The nanowafer can deliver the drug in a controlled release fashion for several weeks, thus increasing the drug residence time on the ocular surface and improving therapeutic efficacy.
Filed on January 17, 2019.
Tell us what you know about Ghanashyam Acharya's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.